NOGOPROOF
Financiado
Towards clinical trials for a novel treatment for stroke
Stroke is the leading cause of adult disability and represents a major health problem in the EU and the Western world. Despite available acute care treatment and rehabilitation therapies, more than half of the patients remain disa...
Stroke is the leading cause of adult disability and represents a major health problem in the EU and the Western world. Despite available acute care treatment and rehabilitation therapies, more than half of the patients remain disabled and there is a large unmet medical need accordingly. Regeneration of interrupted nerve fiber tracts and plastic hardware changes in the adult mammalian central nervous system are extremely restricted, a phenomenon which represents a key reason for the low degree of recovery following CNS injuries including stroke. The molecular impediments that form the basis of this phenomenon are neurite growth inhibitory proteins expressed in central nervous system myelin, in particular the membrane protein Nogo-A which was discovered by our group. Importantly, antibodies directed against Nogo-A have been shown to induce axonal regeneration, enhance plastic circuit rearrangements and mediate significant improvements in functional recovery in rodent and non-human primate models of stroke and spinal cord injury. As recently shown in the ERC advanced grant supported the project ‘Nogorise’, almost full functional recovery was observed in rats with large strokes when anti-Nogo-A antibody treatment was followed by intensive rehabilitative training. As currently no therapy for human stroke patients beyond acute care and rehabilitation exists, there is a substantial market opportunity for the anti- Nogo-A therapy. The proposed activities within the present project aim at further establishing preclinical proof-of-concept for an anti-Nogo-A administration paradigm translatable to human stroke patients and development of human antibodies targeting Nogo-A. The expected data package will allow the critical transition from preclinical to clinical development and support the development of a comprehensive business strategy.
ver más
Duración del proyecto: 20 meses
Fecha Inicio: 2016-12-19
Fecha Fin: 2018-08-31
Fecha Fin: 2018-08-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-08-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2016:
ERC-Proof of Concept-2016
Cerrada
hace 8 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
UNIVERSITAT ZURICH
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
150.90K€ |
Participante